Analytical Data
-
Gene name
OLR1
- Application
-
Alternative Names
C-type lectin domain family 8 member ALectin-like oxidized LDL receptor 1 ;LOX-1 ;Lectin-like oxLDL receptor 1 ;hLOX-1Lectin-type oxidized LDL receptor 1
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P78380
-
Expression Region
58-273aa
-
Molecular Weight
28.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
OLR1, or oxidized low-density lipoprotein receptor 1, is a significant research focus due to its role in cardiovascular diseases and related metabolic disorders. It serves as a receptor for oxidized low-density lipoprotein (oxLDL), which is implicated in the development of atherosclerosis, a condition characterized by the buildup of fatty deposits in the arterial walls. Increased levels of oxLDL are associated with endothelial dysfunction, inflammation, and plaque formation, making OLR1 a critical player in the pathogenesis of cardiovascular diseases. Furthermore, research has shown that OLR1 is involved in various cellular processes, including cell signaling, apoptosis, and the regulation of lipid metabolism. The exploration of recombinant OLR1 proteins has garnered attention as a potential therapeutic approach. By elucidating the structural and functional properties of OLR1 through recombinant technology, researchers aim to develop novel strategies to modulate its activity, thereby offering insights into the prevention and treatment of atherosclerosis and other metabolic syndromes. Understanding the interactions of OLR1 with its ligands and its downstream signaling pathways could lead to innovative therapeutic interventions aimed at reducing cardiovascular risk and improving overall metabolic health. Given the global burden of cardiovascular diseases, research into OLR1 and its recombinant forms holds promise for advancing both our comprehension of fundamental biological processes and the development of targeted therapies.
